Table 3 Evaluation of risk factors for hyperinfection and disseminated infection
Risk factor screened by specific testing or evaluated based on history and physical examination | Pre-implementation (n = 26) | Post-implementation (n = 11) | p-valuea |
|---|---|---|---|
Immunosuppressive drug (%) | |||
Yes | 26 (100.0) | 11 (100.0) | |
No | 0 (0.0) | 0 (0.0) | |
HTLV-1 b (%) | |||
Yes | 8 (30.8) | 8 (80.0) | |
No | 18 (69.2) | 2 (20.0) | 0.011 |
HIV c (%) | |||
Yes | 11 (42.3) | 7 (70.0) | |
No | 15 (57.7) | 3 (30.0) | 0.264 |
Neoplasms (%) | |||
Yes | 26 (100.0) | 11 (100.0) | |
No | 0 (0.0) | 0 (0.0) | – |
Upcoming or current organ transplant (%) | |||
Yes | 26 (100.0) | 11 (100.0) | |
No | 0 (0.0) | 0 (0.0) | – |
Diabetes mellitus (%) | |||
Yes | 26 (100.0) | 11 (100.0) | |
No | 0 (0.0) | 0 (0.0) | – |
End-stage renal disease (%) | |||
Yes | 26 (100.0) | 11 (100.0) | |
No | 0 (0.0) | 0 (0.0) | – |
Peripheral or unexplained eosinophilia (%) | |||
Yes | 25 (96.2) | 10 (90.9) | |
No | 1 (3.8) | 1 (9.1) | 0.512 |
Drug-drug interaction with prescribed therapy, where patient taking at least 1 other prescription medication (%) | |||
Yes | 3 (11.5) | 4 (36.3) | |
No | 9 (34.6) | 2 (18.2) | |
Not applicable | 14 (53.8) | 5 (45.5) | 0.272 |
Country of birth (%) | |||
Yes | 20 (76.9) | 11 (100) | |
No | 6 (23.1) | 0 (0) | 0.151 |